Carl L Gordon - Net Worth and Insider Trading

Carl L Gordon Net Worth

The estimated net worth of Carl L Gordon is at least $886 Million dollars as of 2024-04-27. Carl L Gordon is the Director, 10% Owner of Prevail Therapeutics Inc and owns about 13,822,463 shares of Prevail Therapeutics Inc (PRVL) stock worth over $318 Million. Carl L Gordon is the Director of Turning Point Therapeutics Inc and owns about 2,027,550 shares of Turning Point Therapeutics Inc (TPTX) stock worth over $154 Million. Carl L Gordon is also the Director of Keros Therapeutics Inc and owns about 1,268,734 shares of Keros Therapeutics Inc (KROS) stock worth over $73 Million. Besides these, Carl L Gordon also holds Theseus Pharmaceuticals Inc (THRX) , Alector Inc (ALEC) , Intellia Therapeutics Inc (NTLA) , Terns Pharmaceuticals Inc (TERN) , Compass Therapeutics Inc (CMPX) , ArriVent BioPharma Inc (AVBP) , Adicet Bio Inc (ACET) , ORIC Pharmaceuticals Inc (ORIC) , ACADIA Pharmaceuticals Inc (ACAD) , BioCryst Pharmaceuticals Inc (BCRX) , X4 Pharmaceuticals Inc (XFOR) , Cartesian Therapeutics Inc (RNAC) , Kinnate Biopharma Inc (KNTE) , Pacira BioSciences Inc (PCRX) . Details can be seen in Carl L Gordon's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Carl L Gordon has not made any transactions after 2024-01-30 and currently still holds the listed stock(s).

Transaction Summary of Carl L Gordon

To

Carl L Gordon Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Carl L Gordon owns 22 companies in total, including Prevail Therapeutics Inc (PRVL) , Turning Point Therapeutics Inc (TPTX) , and ORIC Pharmaceuticals Inc (ORIC) among others .

Click here to see the complete history of Carl L Gordon’s form 4 insider trades.

Insider Ownership Summary of Carl L Gordon

Ticker Comapny Transaction Date Type of Owner
PRVL Prevail Therapeutics Inc 2020-06-17 director & 10 percent owner
TPTX Turning Point Therapeutics Inc 2019-04-22 director
ORIC ORIC Pharmaceuticals Inc 2021-03-30 director
KROS Keros Therapeutics Inc 2020-04-13 director
SWTX SpringWorks Therapeutics Inc 2019-09-12 director & 10 percent owner
ALEC Alector Inc 2019-02-11 director & 10 percent owner
ARMO ARMO BioSciences Inc 2018-06-22 director
XFOR X4 Pharmaceuticals Inc 2017-11-20 director & 10 percent owner
NTLA Intellia Therapeutics Inc 2016-05-11 director & 10 percent owner
RNAC Cartesian Therapeutics Inc 2016-06-27 director & 10 percent owner
XLRN Acceleron Pharma Inc 2013-09-18 director
AMRN Amarin Corp PLC 2011-02-28 director
PCRX Pacira BioSciences Inc 2011-02-08 director
BCRX BioCryst Pharmaceuticals Inc 2005-12-02 director
ACAD ACADIA Pharmaceuticals Inc 2005-04-20 director
ACET Adicet Bio Inc 2024-01-25 director
CMPX Compass Therapeutics Inc 2022-11-08 director & 10 percent owner
THRX Theseus Pharmaceuticals Inc 2023-07-17 director & 10 percent owner
KNTE Kinnate Biopharma Inc 2023-05-05 director
IRON Disc Medicine Inc 2021-10-04 director & 10 percent owner
TERN Terns Pharmaceuticals Inc 2022-12-23 director & 10 percent owner
PHGE BiomX Inc 2023-02-27 10 percent owner

Carl L Gordon Latest Holdings Summary

Carl L Gordon currently owns a total of 17 stocks. Among these stocks, Carl L Gordon owns 13,822,463 shares of Prevail Therapeutics Inc (PRVL) as of June 24, 2019, with a value of $318 Million and a weighting of 35.88%. Carl L Gordon owns 2,027,550 shares of Turning Point Therapeutics Inc (TPTX) as of April 22, 2019, with a value of $154 Million and a weighting of 17.39%. Carl L Gordon also owns 1,268,734 shares of Keros Therapeutics Inc (KROS) as of April 13, 2020, with a value of $73 Million and a weighting of 8.28%. The other 14 stocks Theseus Pharmaceuticals Inc (THRX) , Alector Inc (ALEC) , Intellia Therapeutics Inc (NTLA) , Terns Pharmaceuticals Inc (TERN) , Compass Therapeutics Inc (CMPX) , ArriVent BioPharma Inc (AVBP) , Adicet Bio Inc (ACET) , ORIC Pharmaceuticals Inc (ORIC) , ACADIA Pharmaceuticals Inc (ACAD) , BioCryst Pharmaceuticals Inc (BCRX) , X4 Pharmaceuticals Inc (XFOR) , Cartesian Therapeutics Inc (RNAC) , Kinnate Biopharma Inc (KNTE) , Pacira BioSciences Inc (PCRX) have a combined weighting of 38.44% among all his current holdings.

Latest Holdings of Carl L Gordon

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PRVL Prevail Therapeutics Inc 2019-06-24 13,822,463 23.00 317,916,649
TPTX Turning Point Therapeutics Inc 2019-04-22 2,027,550 76.01 154,114,076
KROS Keros Therapeutics Inc 2020-04-13 1,268,734 57.86 73,408,949
THRX Theseus Pharmaceuticals Inc 2023-07-17 17,713,600 4.06 71,917,216
ALEC Alector Inc 2019-02-11 13,094,029 5.25 68,743,652
NTLA Intellia Therapeutics Inc 2016-05-11 2,662,180 20.76 55,266,857
TERN Terns Pharmaceuticals Inc 2022-12-23 7,619,135 4.91 37,409,953
CMPX Compass Therapeutics Inc 2022-11-08 18,791,422 1.45 27,247,562
AVBP ArriVent BioPharma Inc 2024-01-30 1,513,664 15.44 23,370,972
ACET Adicet Bio Inc 2024-01-25 11,447,140 1.68 19,231,195
ORIC ORIC Pharmaceuticals Inc 2021-03-30 2,212,571 8.07 17,855,448
ACAD ACADIA Pharmaceuticals Inc 2005-04-20 621,606 16.71 10,387,036
BCRX BioCryst Pharmaceuticals Inc 2005-12-02 1,100,000 4.16 4,576,000
XFOR X4 Pharmaceuticals Inc 2017-11-20 1,868,966 1.17 2,177,345
RNAC Cartesian Therapeutics Inc 2016-06-27 60,847 21.03 1,279,612
KNTE Kinnate Biopharma Inc 2023-05-05 450,000 2.65 1,192,500
PCRX Pacira BioSciences Inc 2011-02-08 0 26.33 0

Holding Weightings of Carl L Gordon


Carl L Gordon Form 4 Trading Tracker

According to the SEC Form 4 filings, Carl L Gordon has made a total of 1 transactions in Prevail Therapeutics Inc (PRVL) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Prevail Therapeutics Inc is the acquisition of 882,352 shares on June 24, 2019, which cost Carl L Gordon around $15 Million.

According to the SEC Form 4 filings, Carl L Gordon has made a total of 0 transactions in Turning Point Therapeutics Inc (TPTX) over the past 5 years. The most-recent trade in Turning Point Therapeutics Inc is the acquisition of 360,000 shares on April 22, 2019, which cost Carl L Gordon around $6 Million.

According to the SEC Form 4 filings, Carl L Gordon has made a total of 1 transactions in Keros Therapeutics Inc (KROS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Keros Therapeutics Inc is the acquisition of 375,200 shares on April 13, 2020, which cost Carl L Gordon around $6 Million.

More details on Carl L Gordon's insider transactions can be found in the Insider Trading History of Carl L Gordon table.

Insider Trading History of Carl L Gordon

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Carl L Gordon Trading Performance

GuruFocus tracks the stock performance after each of Carl L Gordon's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Carl L Gordon is 7.15%. GuruFocus also compares Carl L Gordon's trading performance to market benchmark return within the same time period. The performance of stocks bought by Carl L Gordon within 3 months outperforms 15 times out of 29 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Carl L Gordon's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Carl L Gordon

Average Return

13.42%

Average return per transaction

Outperforming Transactions

61%

14 out of 23 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 7.57 7.15 17.59 13.42 -5.47 -2.24
Relative Return to S&P 500(%) 6.67 3.49 13.56 4.95 -16.04 -14.34

Carl L Gordon Ownership Network

Ownership Network List of Carl L Gordon

No Data

Ownership Network Relation of Carl L Gordon


Carl L Gordon Owned Company Details

What does Prevail Therapeutics Inc do?

Who are the key executives at Prevail Therapeutics Inc?

Carl L Gordon is the director & 10 percent owner of Prevail Therapeutics Inc. Other key executives at Prevail Therapeutics Inc include director & 10 percent owner Peter A. Thompson , General Counsel Kira M. Schwartz , and Chief Development Officer Franz Hefti .

Prevail Therapeutics Inc (PRVL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Prevail Therapeutics Inc (PRVL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Prevail Therapeutics Inc (PRVL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Prevail Therapeutics Inc (PRVL)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Prevail Therapeutics Inc Insider Transactions

No Available Data

Carl L Gordon Mailing Address

Above is the net worth, insider trading, and ownership report for Carl L Gordon. You might contact Carl L Gordon via mailing address: 601 Lexington Avenue, 54th Floor, New York Ny 10022.

Discussions on Carl L Gordon

No discussions yet.